What this study adds:
- When repurposing medications for new indications we need to be mindful
that safety data cannot always be extrapolated to the new indication.
- In a small cohort 42% of patients experienced at least one adverse
event from treatment with hydroxychloroquine and azithromycin and
7.3% had to stop treatment.
- Clear protocols should be in place to ensure all patients initiated on
novel treatments are monitored closely for adverse events.